Lamotrigine

拉莫三嗪

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameLamotrigine
Drug Alias Name拉莫三秦LamotriginumLamactil拉米克妥Lamictin +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsBipolar II DisorderBipolar I DisorderSolid tumours +[29] 
Global Approved IndicationsBipolar DisorderSeizuresLennox Gastaut Syndrome +[6] 
Approved Indications in ChinaSeizures
Original Approved Country/TerritoryN/A
Original Approved Date1990/01/01
Country/TerritoryBelgiumCanadaUnited States +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesOWP Pharmaceuticals IncGlaxosmithkline PlcBrown University +[6] 
Inactive CompaniesGlaxosmithkline Pharmaceuticals SaMylan Pharmaceuticals IncPharmtechnology Llc +[21] 
Active IndicationsBipolar I DisorderBipolar DisorderFasting +[11] 
Inactive IndicationsBipolar II DisorderSolid tumoursSchizophrenia +[18] 

Other Information

ATC CodeN03AX09
Related LinksWikipediaDrugBankKEGG